Marco Matteo Ciccone
Overview
Explore the profile of Marco Matteo Ciccone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
220
Citations
2094
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bertola S, Margonato D, Roccabruna A, Belli M, Malagoli A, Setti M, et al.
JACC Case Rep
. 2025 Mar;
30(5):103087.
PMID: 40054958
Infective endocarditis (IE) is an uncommon but potentially fatal complication in patients affected by hypertrophic cardiomyopathy (HCM). The risk has been described to be significantly higher than in the general...
2.
Pepe M, Tritto R, Napoli G, Giordano S, Romito R, Biondi-Zoccai G, et al.
J Cardiovasc Pharmacol
. 2025 Feb;
PMID: 39933047
The management of antiplatelet therapy in coronary artery disease (CAD) is one of the most debated topics in cardiology. In some clinical scenarios, such as acute coronary syndromes (ACS) and/or...
3.
Carella M, Forleo C, Dicorato M, Falagario A, Basile P, Carulli E, et al.
JACC Case Rep
. 2024 Dec;
29(23):102795.
PMID: 39691324
A wide range of etiologies, both ischemic and nonischemic, can produce an electrocardiographic pattern of ST-segment elevation (STE), including Takotsubo syndrome (TTS) and electrolyte imbalances. Instances of hypocalcemia-induced TTS and...
4.
Carella M, Forleo C, Caretto P, Naccarati M, Dentamaro I, Dicorato M, et al.
J Clin Med
. 2024 Dec;
13(23).
PMID: 39685654
Anderson-Fabry disease (AFD) remains a therapeutic challenge despite advances in early diagnosis and the availability of enzyme replacement therapies (ERTs). While early initiation of therapy can mitigate disease progression, resistance...
5.
Gargiulo P, Marzano F, Crisci M, Marcucci R, Bruzzese D, Maloberti A, et al.
J Am Coll Cardiol
. 2024 Dec;
85(5):536-540.
PMID: 39665700
No abstract available.
6.
Mazzone F, Giovannico L, Fischetti G, Parigino D, Guaricci A, Forleo C, et al.
Clin Transplant
. 2024 Nov;
38(11):e70031.
PMID: 39585194
No abstract available.
7.
Dicorato M, Basile P, Muscogiuri G, Carella M, Naccarati M, Dentamaro I, et al.
Diagnostics (Basel)
. 2024 Oct;
14(19).
PMID: 39410653
Cardiac amyloidosis (CA) is a cardiac storage disease caused by the progressive extracellular deposition of misfolded proteins in the myocardium. Despite the increasing interest in this pathology, it remains an...
8.
Guaricci A, Monitillo F, Basile P, Di Gennaro D, Dadamo M, Carella M, et al.
Int J Cardiol
. 2024 Oct;
418:132616.
PMID: 39368652
Background: Transfusion-dependent beta thalassemia (TDT) is a genetic disorder characterized by low haemoglobin levels, often leading to myocardial iron overload (MIO) and myocardial fibrosis (MF). Cardiac Magnetic Resonance (CMR) represents...
9.
Paolillo S, Graziani M, Indolfi C, Zaninotto M, Calabro P, Ceriotti F, et al.
G Ital Cardiol (Rome)
. 2024 Sep;
25(10):756-762.
PMID: 39342561
Dyslipidemia is one of the most important risk factors for the development of atherosclerotic disease and its control, through well-proven therapies, allows an optimal risk management over time. LDL-cholesterol targets...
10.
Basile P, Monitillo F, Santoro D, Falco G, Carella M, Khan Y, et al.
J Cardiol
. 2024 Sep;
PMID: 39278346
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have revolutionized the therapeutic scenario of heart failure, demonstrating favorable effects on mortality and quality of life. Previous studies have yielded conflicting data regarding...